Parkinson’s disease · Phase 2
SUNRISE-PD (NE3107-PD-202)
A randomized, placebo-controlled study of bezisterim’s effect on movement symptoms in people with early Parkinson’s disease who had not yet been prescribed levodopa or other dopamine receptor agonists.
Long COVID · Phase 2
ADDRESS-LC (NE3107-LC-201)
A randomized, placebo-controlled study designed to test whether bezisterim can improve brain fog and fatigue in people with Long COVID.
Before considering a study
- Participation is voluntary.
- Eligibility depends on the study protocol and screening.
- Potential risks and potential benefits should be explained through informed consent.
- An investigational therapy may not help and may cause side effects.
- Discuss participation with the study team and your healthcare professional.
For study information
The dedicated study websites provide the most relevant contact and participation information. BioVie cannot provide personal medical advice through this corporate website.
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.
